Single Infusion of Donor Mononuclear Early Apoptotic Cells as Prophylaxis for Graft-versus-Host Disease in Myeloablative HLA-Matched Allogeneic Bone Marrow Transplantation: A Phase I/IIa Clinical Trial

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 1, 2014, Pages 58-65

  Mevorach, Dror ^a   Zuckerman, Tsila ^b   Reiner, Inna ^a   Shimoni, Avichai ^c   Samuel, Simcha ^a   Nagler, Arnon ^c   Rowe, Jacob M ^d   Or, Reuven ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Apoptotic cells; Bone marrow transplantation; Graft versus host disease

Indexed keywords

BILIRUBIN; BUSULFAN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; METHOTREXATE; PROTEIN TYROSINE KINASE INHIBITOR; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APOPTOSIS; APOPTOTIC CELL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DEHYDRATION; DENDRITIC CELL; DRUG TREATMENT FAILURE; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HLA MATCHING; HLA SYSTEM; HOSPITAL DISCHARGE; HUMAN; HYPOTENSION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPROPHYLAXIS; IN VITRO STUDY; KIDNEY FAILURE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; MALE; MIDDLE AGED; MONONUCLEAR CELL; MULTICENTER STUDY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RADIATION DOSE DISTRIBUTION; RENAL REPLACEMENT THERAPY; THROAT IRRITATION; THROMBOCYTE; WHOLE BODY RADIATION; YOUNG ADULT;

APOPTOTIC CELLS; BONE MARROW TRANSPLANTATION; GRAFT-VERSUS-HOST DISEASE;

ADULT; APOPTOSIS; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; LEUKOCYTE COUNT; LEUKOCYTE TRANSFUSION; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RECURRENCE; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84890936248     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.10.010     Document Type: Article

References (34)

1. Appelbaum F.R. Hematopoietic-cell transplantation at 50. NEngl J Med 2007, 357:1472-1475.
2. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. NEngl J Med 2010, 363:2091-2101.
3. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. NEngl J Med 1986, 314:729-735.
4. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96:2062-2068.
5. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998, 92:2303-2314.
6. Bolwell B., Sobecks R., Pohlman B., et al. Aprospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004, 34:621-625.
7. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007, 109:3108-3114.
8. Wagner J.E., Thompson J.S., Carter S.L., Kernan N.A. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 2005, 366:733-741.
9. Eapen M., Logan B.R., Confer D.L., et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007, 13:1461-1468.
10. Hahn T., McCarthy P.L., Zhang M.J., et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. JClin Oncol 2008, 26:5728-5734.
11. Perkins J., Field T., Kim J., et al. Arandomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2010, 16:937-947.
12. Jenkins M.K., Schwartz R.H., Pardoll D.M. Effects of cyclosporine A on Tcell development and clonal deletion. Science 1988, 241:1655-1658.
13. Bacigalupo A., Lamparelli T., Gualandi F., et al. Increased risk of leukemia relapse with high dose cyclosporine after allogeneic marrow transplantation for acute leukemia: 10 year follow-up of a randomized study. Blood 2001, 98:3174-3175.
14. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
15. Fadok V.A., Bratton D.L., Konowal A., et al. Macrophages that have ingested apoptotic cells invitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. JClin Invest 1998, 101:890-898.
16. Amarilyo G., Verbovetski I., Atallah M., et al. iC3b-opsonized apoptotic cells mediate a distinct anti-inflammatory response and transcriptional NF-kappaB-dependent blockade. Eur J Immunol 2010, 40:699-709.
17. Verbovetski I., Bychkov H., Trahtemberg U., et al. Opsonization of apoptotic cells by autologous iC3b facilitates clearance by immature dendritic cells, down-regulates DR and CD86, and up-regulates CC chemokine receptor 7. JExp Med 2002, 196:1553-1561.
18. Krispin A., Bledi Y., Atallah M., et al. Apoptotic cell thrombospondin-1 and heparin-binding domain lead to dendritic-cell phagocytic and tolerizing states. Blood 2006, 108:3580-3589.
19. Kleinclauss F., Perruche S., Masson E., et al. Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent regulatory T-cell expansion. Cell Death Differ 2006, 13:41-52.
20. Li A., Ojogho O., Escher A. Saving death: apoptosis for intervention intransplantation and autoimmunity. Clin Dev Immunol 2006, 13:273-282.
21. Yoo E.K., Rook A.H., Elenitsas R., et al. Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action. JInvest Dermatol 1996, 107:235-242.
22. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
23. Mikl J., Sulkowski M.S., Benhamou Y., et al. Hepatic profile analyses of tipranavir in Phase II and III clinical trials. BMC Infect Disease 2009, 9:203-214.
24. Macias J., Neukam K., Portilla J., et al. Liver tolerance of raltegraviv-contaning antiretroviral therapy in HIV-infected patients with chronic hepatitis C. JAntimicrob Chemother 2011, 66:1346-1350.
25. Parikh C.R., McSweeney P.A., Korular D., et al. Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int 2002, 62:566-573.
26. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. diagnosis and staging. Working report. Biol Blood Marrow Transplant 2005, 11:945-955.
27. Luznik L., Bolaños-Meade J., Zahurak M., et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010, 115:3224-3230.
28. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
29. Lee H.J., Thompson J.E., Wang E.S., Wetzler M. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer 2011, 117:1583-1594.
30. SEER Cancer Statistics Review, 1975-2006 2009, National Cancer Institute, Bethesda, MD, Available at:. http://seer.cancer.gov/csr/1975_2006/, M.J. Horner, L.A.G. Ries, M. Krapcho (Eds.).
31. Reddy P., Ferrara J.L. Immunobiology of acute graft-versus-host disease. Blood Rev 2003, 17:187-194.
32. Mohty M., Blaise D., Faucher C., et al. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2005, 106:4407-4411.
33. Bossard C., Malard F., Arbez J., et al. Plasmacytoid dendritic cells and Th17 immune response contribution in gastrointestinal acute graft-versus-host disease. Leukemia 2012, 26:1471-1474.
34. Tassiulas I., Park-Min K.H., Hu Y., et al. Apoptotic cells inhibit LPS-induced cytokine and chemokine production and IFN responses in macrophages. Hum Immunol 2007, 68:156-164.